An analysis of the bullish investment case for DaVita Inc. highlights its entrenched market position and cash flow discipline, while underscoring the significant regulatory and leverage risks inherent in the kidney care sector.
As Becton Dickinson's complex Reverse Morris Trust transaction nears its 2026 close, analysts argue the market is overlooking a significant value catalyst and an attractively priced remaining business.
State Rep. James Talarico pushes back against claims he called former Congressman Colin Allred a 'mediocre Black man,' attributing the dispute to a misinterpreted private conversation as a heated Democratic primary intensifies.
After years of struggle, Oatly Group AB (OTLY) is showing concrete signs of a sustainable turnaround, posting its first quarterly operating profit in ten years. Strategic moves, including debt restructuring and a key investor stake, are fueling optimism for the oatmilk pioneer's path to profitability.
A new national survey reveals a significant majority of American voters believe the rollout of artificial intelligence is happening too rapidly, coupled with profound doubts about federal regulators' capacity to oversee the technology effectively.
A massive release of Jeffrey Epstein investigation files by the Justice Department has left survivors reeling after personal information, including names and confidential statements, was left unredacted. Lawyers allege a "historic violation" of privacy, prompting urgent calls for judicial intervention.
Pfizer has secured global rights to Novavax's Matrix-M adjuvant technology, aiming to develop new vaccines for infectious diseases as it seeks to diversify its portfolio beyond pandemic-related sales.
Analysts are building a case for Atlassian's long-term growth, citing its accelerating cloud migration, rapid AI adoption, and central role in enterprise workflow orchestration as key drivers, even as revenue recognition shifts create near-term volatility.
Once a high-flying AI discovery platform, AbCellera Biologics is navigating a critical transition to a clinical-stage biotech. With a fortified balance sheet and key Phase 1 readouts on the horizon, some investors see a compelling, albeit risky, turnaround story taking shape.
Once a high-flying SaaS leader, PagerDuty now trades near historic lows despite its critical role in digital operations. As the company navigates a painful pricing model transition, improving fundamentals and persistent takeover speculation present a compelling bull case for patient investors.
Havana acknowledges 'communications' with the Trump administration but stops short of confirming talks, as fuel shortages and U.S. pressure push the island toward a humanitarian brink.
Brussels-based clean transport group Transport & Environment warns that the European Commission's proposed easing of 2035 emissions targets may allow combustion-engine cars to make up half of new sales, marking a significant retreat from earlier climate ambitions.
InSilico Medicine Cayman TopCo's shares have rocketed over 60% in a month, forcing investors to scrutinize whether its AI-driven drug discovery promise can justify the momentum, especially against a backdrop of persistent losses and a negative book value.
As the U.S. dollar softens, Airbnb's extensive international footprint positions it for a potential earnings boost, adding a new layer for investors to consider beyond core travel demand.
After a period of significant volatility, Neogen Corporation (NEOG) is showing signs of a sustainable operational turnaround under new leadership, with its latest quarterly results beating expectations and prompting a rare guidance upgrade.
As McDonald's stock hovers near $315, a closer look reveals a business less about burgers and more about a high-margin global franchise machine. With robust cash flow, aggressive expansion, and a digital ecosystem driving loyalty, analysts see a defensive compounder—if the price is right.
YouTube has taken decisive action against a wave of AI-generated spam content, removing over a dozen popular channels. CEO Neal Mohan emphasizes the platform's commitment to combating deceptive practices as it seeks to protect its ecosystem for viewers and advertisers.
AbbVie's $2.1 billion acquisition of Capstan Therapeutics signals a strategic pivot towards next-generation immunology treatments. The move aims to secure future revenue streams as the company navigates the post-Humira era, with analysts highlighting the transformative potential of its in vivo CAR-T platform.
For retirees, homeownership offers stability but also carries unique financial risks. Financial experts emphasize that a dedicated, liquid cash reserve for unexpected repairs is non-negotiable for protecting a fixed income.
Exclusive BBC analysis reveals nearly half of accredited zoos and aquariums in the UK and Ireland have sounded financial alarms since 2022, forcing tough choices between conservation missions and economic reality.
